Dalteparin and Radiation Therapy in Treating Patients With Newly Diagnosed Supratentorial Glioblastoma Multiforme
Brain and Central Nervous System Tumors
About this trial
This is an interventional treatment trial for Brain and Central Nervous System Tumors focused on measuring adult glioblastoma, adult giant cell glioblastoma, adult gliosarcoma
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically or cytologically confirmed newly diagnosed supratentorial glioblastoma multiforme At least 2 weeks but no more than 4 weeks since prior surgery Patients with biopsy only must be at least 1 week past surgery PATIENT CHARACTERISTICS: Age: 18 and over Performance status: ECOG 0-2 Life expectancy: Not specified Hematopoietic: Platelet count at least 100,000/mm^3 No history of heparin-induced thrombocytopenia No coagulopathy Hepatic: Bilirubin no greater than 2.5 mg/dL AST no greater than 3 times upper limit of normal (ULN) PT/aPTT no greater than 1.5 times ULN Renal: Creatinine no greater than 2.0 mg/dL No gross hematuria within the past 6 months Cardiovascular: No uncontrolled hypertension No unstable angina No symptomatic congestive heart failure No myocardial infarction within the past 6 months No uncontrolled cardiac arrhythmia Gastrointestinal: No peptic ulcer disease within the past 6 months Negative stool guaiac Negative endoscopy required if positive stool guaiac Other: No known hypersensitivity to dalteparin, heparin, or pork products No CNS trauma within the past 3 months No intracranial or intraocular hemorrhage, unless related to surgery, within the past 6 months No retinal detachment within the past 6 months No other concurrent malignancy receiving treatment No active infection No AIDS-related illness HIV negative Must weigh at least 90 pounds (40 kg) Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunomodulators No concurrent investigational matrix metalloproteinase inhibitors or antiangiogenesis agents Chemotherapy: Prior chemotherapy for other malignancy allowed No concurrent standard or investigational cytotoxic chemotherapy Endocrine therapy: Not specified Radiotherapy: No prior cranial irradiation Prior radiotherapy for other malignancy allowed Concurrent radiotherapy allowed Surgery: See Disease Characteristics Recovered from prior surgery No prior eye or ear surgery Other: No concurrent nonsteroidal anti-inflammatory drugs No ongoing or concurrent aspirin or anticoagulation therapy except routine central venous catheter flushing No other concurrent non-protocol therapy
Sites / Locations
- H. Lee Moffitt Cancer Center and Research Institute
- CCOP - Carle Cancer Center
- CCOP - Kalamazoo
- West Michigan Cancer Center
- Mayo Clinic Cancer Center
- CCOP - Metro-Minnesota
- Norris Cotton Cancer Center at Dartmouth-Hitchcock Medical Center
- CCOP - Oklahoma
- Vanderbilt-Ingram Cancer Center at Vanderbilt Medical Center
- CCOP - Scott and White Hospital
- CCOP - St. Vincent Hospital Cancer Center, Green Bay
- University of Wisconsin Comprehensive Cancer Center